EUVIMEDEUVIMED entdecken
Open Access

Phenotypic Effects of a Small Molecule CpxA Phosphatase Inhibitor on Uropathogenic Escherichia coli

Alexis M Stoorza iD, Erin E Carlson iD, Adam S Duerfeldt iD

ACS Infectious Diseases · 11.09.2026 · 12 (9) · 2995-3001

DOI: 10.1021/acsinfecdis.6c00457 ↗

Kurz gefasst

Fachartikel in der Zeitschrift ACS Infectious Diseases, online erschienen am 21.08.2026. Verfasst von Alexis M Stoorza und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicinal Chemistry, University of Minnesota, Minneapolis, Minnesota55414, United States. Hauptthemen laut MEDLINE: Uropathogenic Escherichia coli, Anti-Bacterial Agents, Enzyme Inhibitors, Bacterial Proteins. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIGMS NIH HHS, National Institute of General Medical Sciences.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Patients suffering from Urinary Tract Infections (UTIs) are faced with multidrug resistance and a lack of treatment options. An alternative strategy to traditional bactericidal drug design is to disarm pathogenic bacteria by targeting the regulation of virulence factors. Small-molecule CpxRA phosphatase inhibitor compound 26, hereafter referred to as Cpx26, has shown efficacy in a murine UTI model; however, the impact of pharmacological modulation of CpxRA on bacterial physiology is undefined. Herein, we report the activity of Cpx26 in phenotypic assays to provide insight into its mechanism of action and antivirulence properties. Cpx26 significantly inhibited swimming motility, biofilm formation, and adhesion to bladder epithelial cells at concentrations >60-fold below its MIC. Combination with first-line UTI antibiotics was explored, and synergy was observed with trimethoprim/sulfamethoxazole and fosfomycin, implying potential clinical benefit. This work highlights the potential of antivirulence therapies for prevalent infections such as UTIs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Uropathogenic Escherichia coliAnti-Bacterial AgentsEnzyme InhibitorsBacterial ProteinsEscherichia coli ProteinsHumansBiofilmsBacterial AdhesionMicrobial Sensitivity TestsEpithelial CellsUrinary Tract InfectionsEscherichia coli InfectionsAnimalsVirulenceProtein Kinases

Stichwörter der Autor:innen

AntivirulenceCFT073CpxRATwo-component SystemsUrinary Tract Infections

Substanzen

Anti-Bacterial AgentsEnzyme InhibitorsBacterial ProteinsEscherichia coli ProteinsCpxR protein, BacteriaProtein Kinases

Autor:innen und Institutionen

  • Department of Medicinal Chemistry, University of Minnesota, Minneapolis, Minnesota55414, United States.
  • Department of Chemistry, University of Minnesota, Minneapolis, Minnesota55455, United States.

ORCID-Profile: Alexis M Stoorza, Erin E Carlson, Adam S Duerfeldt

Förderung

  • NIGMS NIH HHS
  • National Institute of General Medical Sciences

Zitieren

APA

Stoorza, A. M., Carlson, E. E., & Duerfeldt, A. S. (2026). Phenotypic Effects of a Small Molecule CpxA Phosphatase Inhibitor on Uropathogenic Escherichia coli. ACS Infectious Diseases, 12(9), 2995-3001. https://doi.org/10.1021/acsinfecdis.6c00457

Vancouver

Stoorza AM, Carlson EE, Duerfeldt AS. Phenotypic Effects of a Small Molecule CpxA Phosphatase Inhibitor on Uropathogenic Escherichia coli. ACS Infectious Diseases. 2026;12(9):2995-3001. doi:10.1021/acsinfecdis.6c00457

BibTeX
@article{Stoorza2026,
  author = {Stoorza, Alexis M and Carlson, Erin E and Duerfeldt, Adam S},
  title = {Phenotypic Effects of a Small Molecule CpxA Phosphatase Inhibitor on Uropathogenic Escherichia coli},
  journal = {ACS Infectious Diseases},
  year = {2026},
  volume = {12},
  number = {9},
  pages = {2995--3001},
  doi = {10.1021/acsinfecdis.6c00457}
}
Kostenlos starten →